Transdermal methimazole treatment in cats with hyperthyroidism.

Area of Science:

• Veterinary Medicine
• Endocrinology
• Pharmacology

Background:

• Hyperthyroidism is a common endocrine disorder in cats.
• Traditional treatments for feline hyperthyroidism include surgery, radioactive iodine therapy, and oral medications.
• Transdermal formulations offer a potential alternative route of administration.

Purpose of the Study:

• To evaluate the efficacy of transdermal methimazole in treating hyperthyroid cats.
• To assess changes in serum thyroxine concentrations following treatment.
• To determine the clinical response and safety of transdermal methimazole therapy.

Main Methods:

• Retrospective evaluation of clinical and laboratory data from 13 hyperthyroid cats.
• Transdermal methimazole formulated in a pleuronic lecithin organogel (PLO) vehicle applied to the inner ear pinna.
• Dosage ranged from 2.5mg/cat every 24 hours to 10.0mg/cat every 12 hours.
• Cats were re-evaluated at approximately 4.3 weeks and 5.4 months post-treatment initiation.

Main Results:

• Significant decreases in serum thyroxine concentrations were observed at both re-evaluation points compared to pretreatment levels.
• Clinical improvement was noted in the treated cats.
• No adverse effects were reported during the study period.

Conclusions:

• Transdermal methimazole is an effective treatment for hyperthyroid cats, leading to significant reductions in thyroxine levels.
• The treatment was well-tolerated, with no adverse effects reported.
• Further investigation into transdermal methimazole is indicated for feline hyperthyroidism management.